Navigation Links
Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center
Date:10/7/2008

Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaccine. While many vaccines attempt to pump up the immune system to fight off a cancer, the new vaccine, Lucanix, is genetically engineered to also trick the cancer into turning off its immune system-suppressing activities.

The first patients have begun enrolling in a new clinical trial at the Moores UCSD Cancer Center testing the effectiveness of the vaccine. The trial will involve 700 patients at some 90 centers worldwide.

Current treatments for advanced lung cancer have limited effectiveness and new therapies are needed, said Lyudmila Bazhenova, M.D., director of the Lung Cancer Unit at the Moores UCSD Cancer Center and assistant clinical professor of medicine at UC San Diego School of Medicine.

"The future treatments for advanced lung cancer may involve combinations of chemotherapy and targeted agents, and possibly even biologicals such as this," she said.

Roughly 430 patients die of lung cancer every day in the United States, according to Bazhenova, making it the nation's number one killer, despite being the second most common cancer. "While breast cancer mortality has declined about 15 percent, there hasn't been much improvement in mortality in lung cancer in the past several decades," she said. According to the American Cancer Society, an estimated 215,000 new cases of lung cancer will be diagnosed, and 162,000 individuals will die from the disease this year in the United States.

The vaccine, developed by NovaRx, a biopharmaceutical company based in San Diego, consists of lung cancer cells that have been genetically altered to shut down the cancer's ability to depress the immune system. In addition, the cells are also modified to enable the immune system to see them better.

Bazhenova explained that earlier tests of the vaccine's effectiveness produced encouraging results. The current trial is for patients with stage four non-small cell lung cancer who have completed four to six cycles of platinum-based chemotherapy. Those patients who have had a response to the treatment, meaning either tumor shrinkage or stable disease, may be eligible. The trial is a double-blind, placebo-controlled study, where neither patients nor doctors know who is getting the vaccine and who may be receiving a placebo. Patients receive injections once a month for 18 months, after which they receive two quarterly injections and are treated until disease progression. The trial's main goal is to determine if the vaccine can improve patient survival compared to taking placebo.


'/>"/>

Contact: Steve Benowitz
sbenowitz@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/18/2017)... ALLENTOWN , Pa. and KALAMAZOO, Mich. ... Allentown, Penn. , and OptiMed Specialty Pharmacy ... a business partnership to offer a strategic hub service ... PMD Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, ... A spirometer is a medical device used ...
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
Breaking Medicine Technology: